61 related articles for article (PubMed ID: 28945315)
1. Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.
Tóth G; Szöllősi J; Vereb G
Cytometry A; 2017 Oct; 91(10):1021-1029. PubMed ID: 28945315
[TBL] [Abstract][Full Text] [Related]
2. Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery.
Sturniolo I; Váróczy C; Bede ÁM; Hegedűs C; Demény MÁ; Virág L
J Vis Exp; 2024 Apr; (206):. PubMed ID: 38738886
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
[TBL] [Abstract][Full Text] [Related]
4. Development, methodological evaluation and application of a cell-based TRF assay for analysis of ADCC activity.
Zhu X; Gong L; Qin Q
J Pharm Biomed Anal; 2023 Oct; 235():115655. PubMed ID: 37647793
[TBL] [Abstract][Full Text] [Related]
5. High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds.
Guti E; Bede ÁM; Váróczy C; Hegedűs C; Demény MÁ; Virág L
J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607075
[TBL] [Abstract][Full Text] [Related]
6. A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays.
Junghans RP
Cancer Immunol Immunother; 1990; 31(4):207-12. PubMed ID: 2379218
[TBL] [Abstract][Full Text] [Related]
7. Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance.
Zahavi DJ; Erbe R; Zhang YW; Guo T; Malchiodi ZX; Maynard R; Lekan A; Gallagher R; Wulfkuhle J; Petricoin E; Jablonski SA; Fertig EJ; Weiner LM
Cancer Biol Ther; 2023 Dec; 24(1):2269637. PubMed ID: 37878417
[TBL] [Abstract][Full Text] [Related]
8. A Mechanism of Resistance to Antibody-Targeted Immune Attack.
Aldeghaither DS; Zahavi DJ; Murray JC; Fertig EJ; Graham GT; Zhang YW; O'Connell A; Ma J; Jablonski SA; Weiner LM
Cancer Immunol Res; 2019 Feb; 7(2):230-243. PubMed ID: 30563830
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory activity of commonly used drugs on Fc-receptor-mediated human natural killer cell activation.
Theorell J; Gustavsson AL; Tesi B; Sigmundsson K; Ljunggren HG; Lundbäck T; Bryceson YT
Cancer Immunol Immunother; 2014 Jun; 63(6):627-41. PubMed ID: 24682538
[TBL] [Abstract][Full Text] [Related]
10. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors.
Bergman I; Basse PH; Barmada MA; Griffin JA; Cheung NK
Cancer Immunol Immunother; 2000 Jul; 49(4-5):259-66. PubMed ID: 10941909
[TBL] [Abstract][Full Text] [Related]
11. Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity.
Nishie M; Suzuki E; Hattori M; Kawaguch K; Kataoka TR; Hirata M; Pu F; Kotake T; Tsuda M; Yamaguchi A; Sugie T; Toi M
Cancer Immunol Immunother; 2021 Mar; 70(3):817-830. PubMed ID: 33000417
[TBL] [Abstract][Full Text] [Related]
12. Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity.
Kwok HF; Buick RJ; Kuehn D; Gormley JA; Doherty D; Jaquin TJ; McClurg A; Ward C; Byrne T; Jaworski J; Leung KL; Snoddy P; McAnally C; Burden RE; Gray B; Lowry J; Sermadiras I; Gruszka N; Courtenay-Luck N; Kissenpfennig A; Scott CJ; Johnston JA; Olwill SA
Mol Cancer; 2011 Dec; 10():147. PubMed ID: 22168338
[TBL] [Abstract][Full Text] [Related]
13. Detection of Antibody-Dependent Cell-Mediated Cytotoxicity-Supporting Antibodies by NK-92-CD16A Cell Externalization of CD107a: Recognition of Antibody Afucosylation and Assay Optimization.
Cruz Amaya J; Walcheck B; Smith-Gagen J; Lombardi VC; Hudig D
Antibodies (Basel); 2023 Jun; 12(3):. PubMed ID: 37489366
[TBL] [Abstract][Full Text] [Related]
14. Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood.
Chowdhury F; Lode HN; Cragg MS; Glennie MJ; Gray JC
Cancer Immunol Immunother; 2014 Jun; 63(6):559-69. PubMed ID: 24658837
[TBL] [Abstract][Full Text] [Related]
15. Toward a Better Understanding of Bioassays for the Development of Biopharmaceuticals by Exploring the Structure-Antibody-Dependent Cellular Cytotoxicity Relationship in Human Primary Cells.
Wieckowski S; Avenal C; Orjalo AV; Gygax D; Cymer F
Front Immunol; 2020; 11():552596. PubMed ID: 33193318
[TBL] [Abstract][Full Text] [Related]
16. Development and implementation of natural killer cell simultaneous ADCC and direct killing assay.
Bennett-Boehm MMC; Mahr AR; Hartwell ST; Regan AK; Weber IS; Blackmon A; Bisson CR; Truong AN; Circo BA; Nienhueser J; Rogers DR; Booher N; Rajagopalan N; Martens JWS; Denton PW
Heliyon; 2023 Dec; 9(12):e22991. PubMed ID: 38125417
[TBL] [Abstract][Full Text] [Related]
17. Real time assays for quantifying cytotoxicity with single cell resolution.
Hsiao SC; Liu H; Holstlaw TA; Liu C; Francis CY; Francis MB
PLoS One; 2013; 8(6):e66739. PubMed ID: 23826123
[TBL] [Abstract][Full Text] [Related]
18. An Antibody-Dependent Cellular Cytotoxicity Assay for Detecting Ocrelizumab Neutralizing Antibody.
Nguyen V; Cheung A; Hendricks R; Peng K; Chung S
AAPS J; 2023 Oct; 25(6):97. PubMed ID: 37783946
[TBL] [Abstract][Full Text] [Related]
19. Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider?
Karlsen EA; Walpole E; Simpson F
Curr Treat Options Oncol; 2024 Mar; 25(3):275-283. PubMed ID: 38270799
[TBL] [Abstract][Full Text] [Related]
20. Sensing antibody functions with a novel CCR8-responsive engineered cell.
Hao J; Lv Y; Xiao X; Li L; Yu C
Acta Biochim Pol; 2024; 71():12185. PubMed ID: 38721308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
